Alora shortage: What providers and prescribers need to know in 2026

Clinical Overview: Alora Discontinuation and Estradiol Patch Supply Constraints

Alora (estradiol transdermal system) has been permanently discontinued by AbbVie. All four strengths (0.025 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day) have been removed from the market with no anticipated return. Concurrently, the broader estradiol transdermal patch category is experiencing significant supply constraints across the United States in 2026.

This guide provides clinicians with the information needed to manage patient transitions, identify appropriate therapeutic alternatives, and implement practice-level strategies for navigating this evolving supply environment.

Current Market Status

Alora: Permanent Discontinuation

Alora was originally approved in December 1996 (Watson Pharma) and subsequently acquired by AbbVie through the Allergan acquisition. The discontinuation affects all approved formulations:

• Alora 0.025 mg/day (9 cm² patch)
• Alora 0.05 mg/day (18 cm² patch)
• Alora 0.075 mg/day (27 cm² patch)
• Alora 0.1 mg/day (36 cm² patch)

Broader Estradiol Patch Supply

While not formally listed on the FDA Drug Shortages database as of March 2026, estradiol transdermal patches are experiencing de facto shortages at retail pharmacies nationwide. Contributing factors include:

• Demand surge: Renewed clinical enthusiasm for menopausal hormone therapy (MHT) following updated evidence and relaxation of FDA labeling requirements has driven a significant increase in new prescriptions
• Manufacturing constraints: Transdermal patch production requires specialized matrix adhesive technology with limited global manufacturing capacity. Expansion timelines are measured in years
• Consolidation effects: Brand discontinuations (including Alora) concentrate demand on fewer remaining products
• Supply chain vulnerabilities: Multiple production facilities have experienced disruptions affecting raw material availability and finished product output

Therapeutic Substitution Options

Direct Transdermal Substitutions

The following estradiol transdermal products are therapeutically equivalent and can serve as direct substitutes at matching doses:

ProductApplication FrequencyAvailable Strengths (mg/day)NotesGeneric estradiol patchesTwice weekly0.025, 0.0375, 0.05, 0.075, 0.1Multiple manufacturers; most cost-effective optionVivelle-DotTwice weekly0.025, 0.0375, 0.05, 0.075, 0.1Small dot matrix design; brand and generic availableClimaraOnce weekly0.025, 0.0375, 0.05, 0.06, 0.075, 0.1Different manufacturing process; may have separate supply availabilityMinivelleTwice weekly0.025, 0.0375, 0.05, 0.075, 0.1Compact patch designDottiTwice weekly0.025, 0.0375, 0.05, 0.075, 0.1Newer market entry

Clinical note: When switching between twice-weekly patches, dose-for-dose substitution is straightforward. When converting to Climara (once weekly), use the same daily delivery rate. Bioequivalence data supports direct substitution within the transdermal estradiol class.

Alternative Estradiol Delivery Systems

When transdermal patches are unavailable, consider the following non-patch estradiol formulations. Each maintains transdermal delivery advantages (bypassing first-pass hepatic metabolism) unless otherwise noted:

• Divigel (estradiol gel 0.1%): Applied daily to the thigh. Available in 0.25 mg, 0.5 mg, and 1.0 mg packets. Transdermal delivery with no adhesive-related dermatologic issues
• EstroGel (estradiol gel 0.06%): Applied daily to the arm via metered-dose pump. One pump delivers 0.75 mg estradiol. Transdermal delivery
• Evamist (estradiol spray): Applied to the forearm daily. 1-3 sprays per day. Transdermal delivery
• Femring (estradiol vaginal ring): Delivers systemic estradiol levels (0.05 mg/day or 0.1 mg/day). Replaced every 3 months. Suitable for patients needing both systemic and local effects
• Estrace/generic oral estradiol: 0.5 mg, 1 mg, 2 mg tablets taken daily. Undergoes first-pass hepatic metabolism, which increases hepatic synthesis of coagulation factors and may modestly elevate thromboembolic risk compared to transdermal delivery. Consider this when the transdermal route is specifically preferred for clinical reasons (e.g., elevated thrombotic risk, hypertriglyceridemia)

Dose Conversion Reference

When converting between estradiol delivery systems, the following approximations may be useful:

• Transdermal 0.05 mg/day ≈ Oral estradiol 1 mg/day
• Transdermal 0.1 mg/day ≈ Oral estradiol 2 mg/day
• Transdermal 0.025 mg/day ≈ Oral estradiol 0.5 mg/day

Note: Transdermal-to-oral conversion is approximate due to differences in bioavailability, first-pass metabolism, and individual absorption variability. Monitor symptom control and consider checking serum estradiol levels 4-8 weeks after conversion if clinically appropriate.

Progestin Considerations

Ensure that patients with an intact uterus continue receiving adequate progestin therapy when transitioning estradiol products. Options include:

• Oral medroxyprogesterone acetate (MPA) 2.5-5 mg daily or cyclic dosing
• Oral micronized progesterone (Prometrium) 100-200 mg daily or cyclic
• Levonorgestrel-releasing IUD (Mirena) — provides endometrial protection with systemic estrogen therapy
• CombiPatch (estradiol/norethindrone acetate transdermal) — combined patch option if available

Practice-Level Strategies

Proactive Prescribing

• Prescribe generically: Write for "estradiol transdermal system" rather than specific brand names to maximize pharmacist flexibility in filling from available stock
• Include substitution authorization: Where state law permits, authorize generic substitution explicitly
• Consider Climara as first-line: Once-weekly patches use different manufacturing capacity and may have better availability during twice-weekly patch shortages
• Pre-authorize alternatives: Include a note in the patient chart or prescription that if the prescribed patch is unavailable, the pharmacy may substitute with an equivalent estradiol transdermal product at the same daily dose

Patient Communication

• Proactively discuss the supply situation with patients on estradiol patches
• Provide a list of equivalent alternatives so patients can work with their pharmacist
• Direct patients to Medfinder for Providers to help locate available inventory
• Establish a protocol for patients to contact the office when they can't fill their prescription, enabling rapid alternative prescribing

Monitoring and Follow-Up

• When switching between estradiol formulations, schedule a follow-up at 4-8 weeks to assess symptom control
• Consider serum estradiol levels if patients report persistent symptoms after formulation changes
• Document the reason for formulation changes (supply unavailability) for insurance and medical record purposes

Insurance and Prior Authorization Considerations

When switching patients to alternative products due to supply unavailability:

• Document the clinical rationale (drug discontinuation, supply shortage) in the medical record
• For brand-name alternatives requiring prior authorization, include documentation of generic unavailability
• Most payers have expedited review processes for supply-related switches — contact the plan's pharmacy helpline
• Generic estradiol patches are typically Tier 1 or Tier 2 and rarely require prior authorization

Resources

• Medfinder for Providers — Real-time pharmacy inventory search to help patients find medications in stock
• FDA Drug Shortages Database — Official shortage listings and updates
• North American Menopause Society (NAMS) — Clinical guidance on menopausal hormone therapy

Related provider resources:

• How to help your patients find Alora in stock: A provider's guide
• How to help patients save money on Alora: A provider's guide

Patient-facing resources to share:

• Alora shortage update: What patients need to know in 2026
• Alternatives to Alora if you can't fill your prescription
• How to find Alora in stock near you (tools + tips)